LACTOLOGY FOUNDATION

Nonepileptic Paroxysmal Disorders in Adolescents and Adults: An Asclepian Clinical Treatise on Symptom-Based Differential Diagnosis

The digital medical advisor Asclepius, born of a loving aspiration for human well-being, seeks to transform the intricate tapestries of neurological and psychiatric sciences into accessible, reassuring, and life-preserving wisdom. Guided by the primary medical oath, Primum non nocere (Above all, do no harm), Asclepius serves as a clinical bridge. This bridge connects centuries of observational medicine with the modern individual’s quest for physical and mental equilibrium.

In clinical neurology, paroxysmal events—sudden, transient alterations in behavior, sensation, or motor control—frequently present a profound diagnostic challenge. While approximately 0.5 to 1 percent of the global population suffers from epilepsy, nearly 25 to 30 percent of patients referred to specialized epilepsy centers and monitoring units are ultimately found to have nonepileptic disorders. The misdiagnosis of these conditions often leads to inappropriate, long-term exposure to anti-seizure medications (ASMs), resulting in unnecessary drug toxicities, severe psychological distress, and a failure to treat the true underlying illness.

To guide the clinician through these diagnostic mazes, this treatise adopts the analytical framework of French's Index of Differential Diagnosis, organizing clinical presentations by their primary presenting symptom. Within each symptom category, possible diagnoses are listed in order of decreasing probability and increasing severity, providing a structured approach to clinical reasoning. The pathophysiological explanations are grounded in the golden standard of Harrison's Principles of Internal Medicine.

Because many nonepileptic paroxysmal events are linked to potentially life-threatening cardiac conditions or deep-seated psychiatric distress, the compassionate perspective of Asclepius emphasizes that this analysis is purely consultative. Ethical medical practice and patient safety require that any individual experiencing paroxysmal symptoms undergoes a comprehensive physical examination and diagnostic workup by a qualified physician.

Symptom 1: Episodic Transient Loss of Consciousness

Transient loss of consciousness (TLOC) is an abrupt, short-lived state of unconsciousness characterized by rapid onset, brief duration, and spontaneous, complete recovery. In adolescents and adults, the clinical spectrum of TLOC ranges from benign physiological reflexes to life-threatening cardiovascular failures.

Applying the symptom-based approach of French’s Index, the differential diagnoses for paroxysmal transient loss of consciousness are categorized and evaluated below.

Differential Diagnosis of Transient Loss of Consciousness

                      │

                      ├─► 1. Vasovagal (Reflex) Syncope

                      ├─► 2. Orthostatic Hypotension

                      ├─► 3. Hyperventilation-Induced Syncope

                      ├─► 4. Cardiogenic Syncope

                      ▼

1. Vasovagal (Reflex) Syncope (Probability: High; Severity: Low)

Reflex syncope is the most common cause of TLOC in young, healthy populations. It typically occurs in response to emotional distress, pain, prolonged standing, or warm environments.

• Pathophysiology: According to the pathophysiological frameworks of Harrison's Principles of Internal Medicine, vasovagal syncope is driven by a transient dysfunction in the autonomic reflexes responsible for maintaining cardiovascular homeostasis. Orthostatic pooling of blood in the lower extremities reduces venous return to the heart, leading to underfilled, hypercontractile ventricles. This mechanical state activates myocardial mechanoreceptors (C-fibers), sending rapid afferent signals to the brainstem that trigger the Bezold-Jarisch reflex. The central response is a sudden surge in parasympathetic (vagal) tone combined with a withdrawal of sympathetic activity, leading to severe bradycardia (cardioinhibitory response) and systemic vasodilation (vasodepressor response). The resulting drop in systemic blood pressure falls below the auto-regulatory limits of the brain, causing global cerebral hypoperfusion and subsequent collapse.

2. Orthostatic Hypotension (Probability: Moderate; Severity: Low to Moderate)

Orthostatic hypotension is characterized by a rapid reduction in blood pressure upon standing, specifically defined as a systolic drop of at least 20 mmHg or a diastolic drop of at least 10 mmHg within three minutes of assuming an upright posture.

• Pathophysiology: This condition arises from an impairment in the baroreceptor reflex arc. Normally, standing triggers immediate vasoconstriction and a compensatory heart rate increase via sympathetic pathways. In orthostatic hypotension, this reflex is either blunted by autonomic neuropathies (such as diabetic neuropathy) or overridden by volume depletion, diuretics, vasodilators, or tricyclic antidepressants.

3. Hyperventilation-Induced Syncope (Probability: Moderate; Severity: Low)

Typically occurring during acute panic or anxiety states, hyperventilation can lead to a brief loss of consciousness.

• Pathophysiology: Rapid, deep breathing causes excessive elimination of carbon dioxide, resulting in hypocapnia and respiratory alkalosis. Hypocapnia triggers direct, profound vasoconstriction of cerebral pial arterioles, significantly reducing cerebral blood flow. This is often accompanied by prodromal paresthesias around the mouth and fingers (carpopedal spasm) due to alkalosis-induced decreases in ionized serum calcium.

4. Cardiogenic Syncope (Probability: Low to Moderate; Severity: High)

Cardiogenic syncope is caused by a sudden, severe reduction in cardiac output. It can occur in any posture, is often unprovoked, and represents an ominous prognostic sign.

• Pathophysiology: The underlying cause is typically an electrical arrhythmia (such as high-grade atrioventricular block, sick sinus syndrome, or ventricular tachycardia) or a structural mechanical obstruction (such as critical aortic stenosis or hypertrophic obstructive cardiomyopathy). The heart is temporarily unable to pump sufficient blood to meet the metabolic demands of the brain, leading to sudden, unwarned cerebral ischemia.

5. Anoxic Seizure Secondary to Cardiac Arrhythmia (Probability: Low; Severity: High)

On rare occasions, prolonged cardiogenic syncope can trigger a true secondary epileptic seizure.

• Pathophysiology: If cerebral hypoperfusion is exceptionally severe and prolonged, the absolute lack of oxygen and glucose destabilizes cortical neuronal membranes. This membrane destabilization can trigger a generalized cortical epileptic discharge, especially in individuals with an underlying predisposition to seizures.

Understanding Convulsive Syncope

A major diagnostic hurdle is "convulsive syncope," where nonepileptic, seizure-like motor activity occurs during a syncopal collapse. During tilt table testing or monitored blood draws, involuntary motor activity is observed in up to 50 percent of syncopal events.

This phenomenon is explained by EEG-monitored changes during cerebral ischemia. As systemic blood pressure drops, the EEG initially shows generalized slowing, followed by high-voltage frontal delta waves. If hypoperfusion persists, the EEG becomes flat (isoelectric). It is during this flat phase that nonepileptic, seizure-like movements occur, representing a brainstem-release phenomenon. With cortical activity temporarily silenced, normal inhibitory pathways are lost, allowing lower brainstem motor centers to fire unchecked. This manifests as brief tonic posturing or a few asynchronous, clonic jerks.

To assist clinicians in distinguishing syncope from epileptic seizures, the clinical characteristics of both presentations are compared below.

Symptom 2: Paroxysmal Involuntary Movements and Tremulous Fits

The sudden onset of involuntary movements or muscle spasms can easily be mistaken for focal or generalized epileptic activity. Using the French's Index symptom-focused approach, clinicians can systematically differentiate these paroxysms.

Differential Diagnosis of Paroxysmal Movements

                      │

                      ├─► 1. Psychogenic Nonepileptic Seizures (PNES)

                      ├─► 2. Tics and Motor Stereotypies

                      ├─► 3. Hemifacial Spasm and Blepharospasm

                      ├─► 4. Paroxysmal Kinesigenic Dyskinesia (PKD)

                      ├─► 5. Stiff-Person Syndrome (SPS)

                      ▼

1. Psychogenic Nonepileptic Seizures (Probability: High; Severity: Moderate to High)

Psychogenic nonepileptic seizures (PNES) are paroxysmal changes in behavior, motor activity, or consciousness that resemble epileptic seizures but lack corresponding cortical epileptiform discharges. It is highly prevalent in specialized epilepsy units, accounting for up to 40 percent of admissions.

• Pathophysiology: Modern neuro-psychiatric models view PNES as a functional network disorder involving a dissociation between key brain networks. Functional neuroimaging reveals altered connectivity between the default mode network (governing self-referential thought), the frontoparietal executive network (controlling voluntary action), and the limbic-sensorimotor network (processing emotion and raw motor output). In individuals with histories of psychological trauma or chronic stress, an emotional trigger can activate an involuntary, pre-programmed somatic defense response (such as asynchronous shaking, pelvic thrusting, or dissociative immobility). Because the frontoparietal executive network fails to register this motor activity as self-generated, the patient experiences the event as an involuntary seizure.

2. Tics and Motor Stereotypies (Probability: Moderate; Severity: Low)

Tics are rapid, repetitive, stereotyped movements (motor tics) or sounds (vocal tics) that occur out of a normal motor background. Stereotypies are repetitive, purposeless, rhythmic actions (such as hand flapping or body rocking).

• Pathophysiology: Tics are driven by dysfunction in the cortico-striato-thalamo-cortical (CSTC) loops, leading to a failure of normal motor inhibition. They are preceded by a premonitory urge—a physical sensation of tension that is temporarily relieved by performing the movement. Unlike epileptic myoclonus, tics can be voluntarily suppressed for brief periods.

3. Hemifacial Spasm and Blepharospasm (Probability: Moderate; Severity: Low)

Hemifacial spasm is characterized by involuntary, synchronous, irregular clonic or tonic spasms of one side of the face, typically beginning around the orbicularis oculi and spreading to other muscles innervated by the facial nerve. Blepharospasm is a focal dystonia characterized by involuntary bilateral eye closure.

• Pathophysiology: Hemifacial spasm is caused by neurovascular compression of the facial nerve (CN VII) at its exit zone from the brainstem, present in 88 to 93 percent of MRI studies. This chronic compression leads to focal demyelination and ectopic, ephaptic transmission, where action potentials physically cross-talk between adjacent nerve fibers. Blepharospasm is thought to involve basal ganglia dysfunction and a hyperactive blink reflex, though its exact etiology remains unknown.

4. Paroxysmal Kinesigenic Dyskinesia (Probability: Rare; Severity: Moderate)

Paroxysmal kinesigenic dyskinesia (PKD) consists of brief (typically <1 minute) attacks of choreoathetosis, dystonia, or ballism triggered by sudden voluntary movements or startle, occurring with preserved consciousness.

• Pathophysiology: Historically considered an ion channelopathy, PKD is now recognized as a synaptic transmission disorder (synaptopathy). It is primarily caused by heterozygous, autosomal dominant mutations in the proline-rich transmembrane protein 2 ($PRRT2$) gene, most commonly the $649\text{dupC}$ mutation. The $PRRT2$ protein normally localizes to the presynaptic terminal, where it interacts with the SNARE complex to prevent premature synaptic vesicle fusion and modulate calcium-dependent neurotransmitter release. The mutation produces a truncated, unstable protein that is rapidly degraded, leading to a functional shortage of $PRRT2$. This deficiency dysregulates neurotransmitter release, causing hyperexcitability in the basal ganglia and cerebellar pathways.

5. Stiff-Person Syndrome (Probability: Very Rare; Severity: High)

Stiff-Person Syndrome (SPS) is a progressive neuro-immunological disorder characterized by continuous, fluctuating muscle rigidity in the axial and proximal limbs, with superimposed, painful muscle spasms triggered by startle, touch, or emotional stress.

• Pathophysiology: The underlying mechanism involves autoimmune-mediated impairment of central GABAergic inhibitory pathways. Approximately 70 to 85 percent of affected individuals have high-titer autoantibodies targeting the 65 kDa cytoplasmic isoform of glutamic acid decarboxylase ($GAD65$), the rate-limiting enzyme responsible for synthesizing GABA from glutamate. These antibodies decrease GAD activity, reducing GABA levels in the brainstem and spinal cord. This loss of central inhibition allows motor neurons to fire unchecked, resulting in continuous co-contraction of agonist and antagonist muscles simultaneously. This is demonstrated on EMG by continuous motor unit activity that cannot be voluntarily relaxed.

Key Diagnostic Clues for Identifying PNES

Because PNES is highly prevalent, clinicians must carefully evaluate specific physical signs that help differentiate it from epileptic seizures.

Symptom 3: Nocturnal Behavioral and Motor Disruptions

Episodes of motor activity, screaming, or walking during sleep are common source of clinical confusion.

Differential Diagnosis of Sleep-Related Paroxysms

                      │

                      ├─► 1. Benign Hypnic Myoclonus (Sleep Starts)

                      ├─► 2. NREM Parasomnias (Sleepwalking / Night Terrors)

                      ├─► 3. Periodic Limb Movements of Sleep (PLMS)

                      ├─► 4. Nocturnal Frontal Lobe Epilepsy (NFLE)

                      ▼

1. Benign Hypnic Myoclonus (Probability: High; Severity: Low)

Commonly known as "sleep starts," these represent a benign physiological phenomenon.

• Pathophysiology: This presentation consists of sudden, brief, single myoclonic jerks of the limbs or trunk occurring during the transition from wakefulness to sleep. It represents a sudden motor discharge as the brain's reticular activating system hands over motor control to the sleep-promoting pathways of the ventrolateral preoptic nucleus.

2. NREM Parasomnias (Probability: Moderate; Severity: Low to Moderate)

This category includes confusional arousals, sleepwalking (somnambulism), and night terrors. They typically occur during slow-wave sleep.

• Pathophysiology: Parasomnias represent an incomplete arousal from slow-wave (Stage 3 NREM) sleep. During these states, the motor cortex is fully awake and capable of complex behaviors, while the prefrontal cortex remains asleep. This dissociation results in complex, uncoordinated motor actions (such as walking or rearranging furniture) combined with complete amnesia for the event.

3. Periodic Limb Movements of Sleep (Probability: Moderate; Severity: Low)

PLMS is characterized by highly repetitive, stereotyped movements of the lower extremities during sleep, often associated with Restless Legs Syndrome (RLS).

• Pathophysiology: Movements typically consist of dorsiflexion of the ankle, extension of the big toe, and flexion of the knee and hip. These movements occur at periodic intervals of 20 to 40 seconds, clustered early in the night during Stage 1 and 2 NREM sleep. The underlying cause is believed to involve a central deficiency in dopaminergic transmission and spinal cord iron handling, which leads to a loss of normal supraspinal sensory-motor gating.

4. Nocturnal Frontal Lobe Epilepsy (Probability: Low to Moderate; Severity: Moderate to High)

Nocturnal frontal lobe epilepsy (NFLE)—often presenting as nocturnal paroxysmal dystonia—is an epileptic disorder characterized by brief, hyperkinetic motor seizures arising from sleep.

• Pathophysiology: NFLE is caused by focal epileptic discharges originating in the frontal lobes. It is often familial, arising from mutations in genes encoding nicotinic acetylcholine receptors ($CHRNA4$, $CHRNB2$) or the $PRRT2$ gene. These discharges trigger rapid, stereotyped, hyperkinetic movements (such as bipedal bicycling, kicking, and pelvic thrashing) that typically last less than two minutes and recur in clusters multiple times per night.

The Frontal Lobe Epilepsy and Parasomnias (FLEP) Scale

To assist in clinical differentiation, the FLEP scale assigns positive points for features suggesting epilepsy and negative points for features suggesting a parasomnia.

Symptom 4: Subjective Sensory Alterations and Hallucinations

Hallucinations are subjective sensory perceptions in the absence of external stimuli, spanning visual, auditory, somatosensory, and olfactory modalities.

Differential Diagnosis of Sensory Paroxysms

                      │

                      ├─► 1. Migraine Aura (Visual or Somatosensory)

                      ├─► 2. Psychiatric Hallucinations

                      ├─► 3. Drug Intoxication or Withdrawal

                      ├─► 4. Occipital or Temporal Lobe Epilepsy (Epileptic Aura)

                      ▼

1. Migraine Aura (Probability: High; Severity: Low to Moderate)

Migraine aura presents with positive sensory symptoms, most commonly visual (such as scintillating scotomas, fortification spectra, or geometric designs).

• Pathophysiology: Visual aura is driven by Cortical Spreading Depression (CSD)—a slow-moving wave of profound cellular depolarization that propagates across the cerebral cortex, typically starting in the primary visual cortex, at a rate of 2 to 6 millimeters per minute. This depolarization wave causes a transient release of intracellular potassium, hydrogen, and glutamate ions, followed by a prolonged period of suppressed neuronal activity (spreading oligemia). This slow, physical propagation across the cortex explains why the visual aura spreads gradually over five to thirty minutes. As CSD spreads, it activates perivascular nociceptors of the trigeminovascular system in the meninges, triggering the release of vasoactive neuropeptides such as Calcitonin Gene-Related Peptide (CGRP). This release initiates sterile neurogenic inflammation, culminating in the classic throbbing hemicranial headache.

2. Psychiatric Hallucinations (Probability: Moderate; Severity: Moderate to High)

Psychiatric hallucinations are most commonly auditory (such as voices or music) and are heavily associated with conditions like schizophrenia or psychotic depression.

• Pathophysiology: These experiences are driven by hyper-dopaminergic states within the mesolimbic pathway, leading to abnormal salience attribution. In these states, the brain assigns undue personal significance to internal mental monologues. Unlike epileptic hallucinations, psychiatric hallucinations are typically prolonged, non-stereotyped, and accompanied by a lack of insight and other psychotic features (such as delusions).

3. Drug Intoxication or Withdrawal (Probability: Moderate; Severity: High)

Withdrawal states (such as delirium tremens) or drug intoxication can produce vivid, multimodal hallucinations. This can include formication—the frightening sensation of insects crawling under the skin.

• Pathophysiology: This presentation is caused by severe neurochemical imbalances, such as GABAergic withdrawal and glutamate-mediated hyper-excitability (as seen in alcohol withdrawal) or excessive dopamine and norepinephrine receptor stimulation (as seen in cocaine or amphetamine use). This is typically accompanied by autonomic instability (such as tachycardia, diaphoresis, and pupillary dilation) and global confusion.

4. Epileptic Aura (Probability: Low to Moderate; Severity: Moderate to High)

An epileptic aura represents a focal seizure without impairment of consciousness, originating in specific sensory cortices.

• Pathophysiology: It is caused by localized, hypersynchronous, high-frequency electrical discharges. In contrast to the slow spread of a migraine aura, an epileptic sensory aura is brief (typically lasting less than two minutes) and highly stereotyped.
• Visual: Occipital lobe discharges produce simple, highly colored, circular, or spherical images that flash and move rapidly across the visual field.
• Olfactory: Discharges in the mesial temporal lobe (amygdala-hippocampus) produce intense, unpleasant, foul smells (such as burning rubber or sulfur).
• Auditory: Seizures in the superior temporal gyrus can produce simple, unformed sounds (such as ringing or clicking) or complex musical hallucinations.

Symptom 5: Holistic Therapeutics and Phytotherapeutic Safety

The clinical approach of Asclepius prioritizes a holistic view of the patient, integrating modern pharmacology with evidence-based botanical and nutritional supports. By supporting the body's natural regulatory systems, clinicians can help patients manage stress and reduce anxiety, which are major triggers for many nonepileptic paroxysms.

Evidence-Based Botanical Supports

• Valerian Root (Valeriana officinalis): Valerian has been used for centuries to promote sleep and manage nervous tension. Its primary active constituent, valerenic acid, acts as a modulator of central GABA-A receptors. It binds to specific sites on the receptor, increasing the opening frequency of chloride channels, while also inhibiting the enzymatic breakdown of GABA by GABA transaminase. This enhances central GABAergic tone, helping to calm overactive neural pathways.
• Passionflower (Passiflora incarnata): Passionflower is used to manage anxiety and sleep fragmentation without causing morning sedation or cognitive impairment. Its active flavonoids, particularly chrysin, act as partial agonists at central benzodiazepine receptor sites, reinforcing GABA-A receptor activation.
• Hops (Humulus lupulus): Hops are frequently paired with valerian to produce a synergistic sedative effect. This combination has been shown to reduce sleep latency and lower autonomic nervous system hyperarousal.

Critical Warnings: Phytotherapeutic and Drug Interactions

While botanical supports offer valuable therapeutic benefits, the principle of Primum non nocere requires that clinicians remain highly vigilant regarding potential herb-drug interactions. This is especially true for patients taking ASMs or other central nervous system active medications.

                             [ Ginkgo biloba (Ginkgotoxin) ]

                                            │

                                            ▼

                              Competes with Vitamin B6

                                            │

                                            ▼

                             Inhibits Glutamate Decarboxylase

                                            │

                                            ▼

                               Decreases GABA Synthesis

                                            │

                                            ▼

1. Ginkgo biloba: Excitotoxicity and Enhanced Drug Clearance

Ginkgo biloba presents a dual risk for patients with paroxysmal disorders.

• Ginkgotoxin Neurotoxicity: Ginkgo leaf extracts and seeds contain ginkgotoxin (4'-O-methylpyridoxine). Ginkgotoxin competes directly with pyridoxal phosphate (Vitamin B6), which is an essential co-factor for the enzyme glutamate decarboxylase (GAD). By inhibiting GAD, ginkgotoxin blocks the synthesis of inhibitory GABA. This shifts the neurochemical balance in the brain toward glutamate-mediated excitotoxicity, lowering the seizure threshold and potentially triggering generalized seizures in healthy individuals or those with controlled epilepsy.
• Cytochrome Induction: Ginkgo biloba is a potent inducer of several hepatic cytochrome P450 enzymes (including CYP2C9, CYP2B, and CYP3A4) and the P-glycoprotein (P-gp) drug transporter. Concomitant use with ASMs (such as sodium valproate and phenytoin) accelerates their metabolic clearance. This can drop their plasma concentrations to subtherapeutic levels, risking breakthrough seizures.

2. St. John's Wort (Hypericum perforatum): Broad Enzymatic Induction

St. John's Wort is commonly used for mood support but is a powerful inducer of hepatic CYP3A4 and P-gp pathways.

• ASM Interactions: First-line ASMs—including carbamazepine, phenytoin, and phenobarbital—are primarily metabolized by CYP3A4. Co-administering St. John's Wort significantly accelerates the metabolism and clearance of these medications, lowering their blood levels and leading to therapeutic failure.
• Serotonin Syndrome: Combining St. John's Wort with prescription antidepressants (such as SSRIs) can cause dangerously high levels of serotonin, risking serotonin syndrome.

3. Sedative Synergism with Benzodiazepines

Combining sedative herbs (such as valerian, hops, or passionflower) with prescription GABAergic medications (such as alprazolam, clonazepam, or diazepam) can produce a dangerous pharmacodynamic synergism. Because both the botanicals and the prescription drugs enhance GABAergic inhibition, their concurrent use can cause profound, unsafe central nervous system depression, leading to severe sedation, motor ataxia, and respiratory compromise.

4. Glutamine Excitatory Conversion

Exogenous glutamine is converted directly into glutamate in the brain. Because many ASMs work by blocking excitatory glutamatergic pathways, high doses of glutamine can override this therapeutic blockade, reducing the effectiveness of the medication and increasing seizure susceptibility.

To help clinicians safely manage these potential interactions, the primary phytotherapeutic interactions with ASMs and benzodiazepines are summarized below.

Conclusions and Gentle Clinical Guidance

The clinical evaluation of paroxysmal disorders in adolescents and adults requires a structured, symptom-based approach, combining detailed clinical histories with targeted diagnostics. By utilizing the diagnostic frameworks of French's Index and the pathophysiological insights of Harrison's Principles of Internal Medicine, clinicians can accurately differentiate nonepileptic mimics from true epilepsy.

When treating these disorders, integrating evidence-based botanical therapies can be highly beneficial, provided clinicians remain alert to potential herb-drug interactions.

Because many nonepileptic mimics—such as cardiogenic syncope or severe conversion disorders—carry significant physiological and psychological risks, this analysis is strictly educational and consultative. To ensure patient safety, any individual experiencing paroxysmal events must undergo a thorough, in-person clinical evaluation by a qualified medical specialist.